Insomnia associated with patient-reported outcomes in head and neck cancer survivors
Supportive Care in Cancer · 2025
DOI: 10.1007/s00520-025-09995-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Purva H Rumde und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Pittsburgh, School, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Patient Reported Outcome Measures, Cancer Survivors, Head and Neck Neoplasms. Die Arbeit nennt 57 Literaturangaben.
Themen: Schlaf
Abstract (Originalsprache)
PURPOSE: To investigate the prevalence and risk factors of insomnia and to explore associations between insomnia and patient-reported outcomes in head and neck cancer (HNC) survivors. METHODS: Cross-sectional analysis was performed on questionnaires completed by survivors with primary squamous cell carcinoma of the oral cavity, oropharynx, or laryngopharynx seen in a multidisciplinary HNC survivorship clinic from August 2018 to August 2022 at a single academic medical center. Insomnia, quality of life (QOL), and symptoms of dysphagia severity, anxiety, and depression were assessed using the Insomnia Severity Index, University of Washington QOL, Eating Assessment Tool-10, Generalized Anxiety Disorder 7-item, and Patient Health Questionnaire-8. Multivariable regression analysis and trend tests were used to evaluate these relationships. RESULTS: A total of 827 HNC survivors, median 9 months post-treatment, were included. Tumors were most commonly oropharyngeal (51.0%), T stage 1-2 (57.3%), and treated by surgery with adjuvant radiation/chemoradiation (45.5%). Of the survivors, 21.4% of patients reported subthreshold insomnia, and 13.1% had clinical insomnia. Insomnia was associated with worse physical and social-emotional QOL scores and greater symptoms of anxiety, depression, dysphagia, and neck disability (all p < 0.001). CONCLUSIONS: The prevalence of insomnia among HNC survivors is 34.5%. Insomnia was associated with decreased QOL and higher symptom burden, including anxiety, depression, dysphagia, and neck disability. IMPLICATIONS FOR SUPPORTIVE CARE IN SURVIVORS OF HNC: Screening for insomnia should be considered in HNC survivorship care to identify individuals who may benefit from comprehensive interventions that include sleep-focused strategies, which could also improve patient-reported outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, University of Pittsburgh, School, Pittsburgh, PA, USA.
- Division of Internal Medicine, Grossman School of Medicine, New York University, New York, NY, USA.
- Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
- Department of Otolaryngology-Head & Neck Surgery, School of Medicine, University of Pittsburgh, PA, Pittsburgh, USA.
- Santa Clara Valley Medical Center, San Jose, CA, USA.
- Department of Otolaryngology-Head & Neck Surgery, School of Medicine, University of Pittsburgh, PA, Pittsburgh, USA. mlf981@pitt.edu.
Zitieren
APA
Rumde, P. H., Awad, D. R., Li, J., Contrera, K. J., Dharmarajan, H., Harris, A., Harrison, C., Soose, R. J., Johnson, J., & Nilsen, M. L. (2025). Insomnia associated with patient-reported outcomes in head and neck cancer survivors. Supportive Care in Cancer. https://doi.org/10.1007/s00520-025-09995-5
Vancouver
Rumde PH, Awad DR, Li J, Contrera KJ, Dharmarajan H, Harris A, et al. Insomnia associated with patient-reported outcomes in head and neck cancer survivors. Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-09995-5
BibTeX
@article{Rumde2025,
author = {Rumde, Purva H and Awad, Daniel R and Li, Jinhong and Contrera, Kevin J and Dharmarajan, Harish and Harris, Alexandria and Harrison, Christine and Soose, Ryan J and Johnson, Jonas and Nilsen, Marci L},
title = {Insomnia associated with patient-reported outcomes in head and neck cancer survivors},
journal = {Supportive Care in Cancer},
year = {2025},
doi = {10.1007/s00520-025-09995-5}
}
EUVIMED